UPBS Upstream Biosciences, Inc. featured news, full reports, and detailed charts
Upstream Biosciences, Inc. (UPBS/UPBS.OB) Wrap Up:
Upstream Biosciences, Inc., a biotechnology company, discovers, develops, and licenses genetic diagnostic biomarkers for cancer susceptibility and drug response. Its proprietary data mining pipeline enables it to locate and analyze genetic variations in the regions of DNA ‘upstream’ of the gene, the ‘gene switches’, which control the quantities and timing of expression of the genes, and proteins important to disease and drug response. The company’s lead products include UBLC-1001, a genetic marker for liver cancer susceptibility; UBPC-1001, a genetic marker for prostate cancer susceptibility; UBOC–1001, a genetic marker for ovarian cancer; and UBTC–1001, a genetic marker for thyroid cancer. ...Upstream Biosciences, Inc. (UPBS:OTC Bulletin Board Market)
Snapshot of Upstream Biosciences, Inc. (UPBS)
|
OPEN
--
|
PREVIOUS CLOSE
$0.02
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
09/4/09 - $0.25
|
52 WEEK LOW
09/4/09 - $0.02
|
|
|
MARKET CAP
1.0M
|
AVERAGE VOLUME 3 mo
18.4K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
49.5M
|
|
|
UPBS Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
UPBS Top Compensated Officers
Executives, Board Directors
Key developments for Upstream Biosciences, Inc. (UPBS)
Effective September 03, 2009, Upstream Biosciences Inc. changed its OTCBB stock ticker symbol to UPBS from UPBSE.
Upstream Biosciences Inc. announced that effective August 28, 2009, Joel Bellenson was appointed the CFO of the company following the resignation of Tim Fernback on the same date.
Upstream Biosciences Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2009. For the quarter, the company reported loss before income tax of $213,911 and net loss and comprehensive loss for the period of $211,039 against loss before income tax of $447,137 and net loss and comprehensive loss for the period of $447,137 or $0.01 per basic and diluted share a year ago. For the nine months, the company reported loss before income tax of $873,494 and net loss and comprehensive loss for the period of $864,880 or $0.02 per basic and diluted share against loss before income tax of $1,636,681 and net loss and comprehensive loss for the period of $1,636,681 or $0.03 per basic and diluted share a year ago. Net cash used in operating activities was $300,344 against $704,285 a year ago.
UPBS Competitors
| Company | Last | Change |
| Compugen Ltd | $2.84 USD | +0.048 |
| Diagnocure Inc | C$1.00 CAD | -0.01 |
| Epigenomics | €3.39 EUR | +0.03 |
| Myriad Genetics Inc | $23.46 USD | +0.50 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | UPBS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
UPBS |
||
UPBS transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||